Gaudium IVF Q2 FY27 consolidated revenue Rs 37.41 cr, PAT Rs 9.41 cr

Gaudium IVF Q2 FY27 consolidated revenue Rs 37.41 cr, PAT Rs 9.41 cr

Gaudium IVF and Women Health Ltd reported Q2 FY27 consolidated revenue from operations of Rs 37.41 cr and PAT of Rs 9.41 cr, versus Rs 31.73 cr and Rs 9.38 cr in Q2 FY26.

Gaudium IVF and Women Health Ltd
Gaudium IVF and Women Health LtdReviewed and published by · How we report
1 min read
gaudium ivfq2 fy27earningshealthcareresults
ShareWhatsAppXLinkedIn

Key takeaways

  • Rs 37.41 cr revenue from operations in Q2 FY27 vs Rs 31.73 cr in Q2 FY26
  • Rs 13.47 cr EBITDA (Ex. Other Income) in Q2 FY27 vs Rs 13.76 cr a year earlier
  • Rs 9.41 cr PAT in Q2 FY27 vs Rs 9.38 cr in Q2 FY26
  • EBITDA Margins % at 36.00% in Q2 FY27 vs 43.37% in Q2 FY26
  • PAT Margins % at 25.16% in Q2 FY27 vs 29.56% in Q2 FY26

Q2 FY27 · consolidated

MetricSep 2026Sep 2025Change
RevenueRs 37.41 crRs 31.73 cr+17.9%
PATRs 9.41 crRs 9.38 cr+0.4%

As reported in the filing. Figures are transcribed, not computed.

What the numbers show

  • Net margin was 25.15% of revenue, down 440 bps from 29.56%.

• Revenue from operations (Q2 FY27, consolidated): Rs 37.41 cr (Q2 FY26: Rs 31.73 cr)

• EBITDA (Ex. Other Income) (Q2 FY27, consolidated): Rs 13.47 cr (Q2 FY26: Rs 13.76 cr)

• PAT (Q2 FY27, consolidated): Rs 9.41 cr (Q2 FY26: Rs 9.38 cr)

• EBITDA Margins % (Q2 FY27, consolidated): 36.00% (Q2 FY26: 43.37%)

• PAT Margins % (Q2 FY27, consolidated): 25.16% (Q2 FY26: 29.56%)

According to the consolidated statement of financial results summarised in the investor presentation’s “Financial Statement (Rs. Lakhs) Consolidated” table, Gaudium IVF and Women Health Ltd’s revenue from operations for the quarter ended 30 September 2026 (Q2 FY27) was Rs 37.41 cr, up from Rs 31.73 cr in the corresponding quarter a year earlier (Q2 FY26).

Consolidated EBITDA (Ex. Other Income) for Q2 FY27 was Rs 13.47 cr, compared with Rs 13.76 cr in Q2 FY26. The company-reported EBITDA Margins % stood at 36.00% in Q2 FY27 versus 43.37% in Q2 FY26, as presented in the same table.

On the bottom line, consolidated PAT for Q2 FY27 was Rs 9.41 cr, marginally higher than Rs 9.38 cr in Q2 FY26. The reported PAT Margins % were 25.16% in Q2 FY27, compared with 29.56% in the year-ago quarter.

In the comments accompanying the consolidated financial statement in the investor presentation, the company states that revenue growth in Q2 FY27 was driven mainly by the IVF business. It further states that EBITDA and PAT remained largely flat due to the marketing strategy and costs associated with rolling out new hubs, which are still in their early ramp-up phase and carry high fixed costs, and that these effects were partly offset by the hospital and pharmacy businesses.

Track Gaudium IVF and Women Health Ltd

Cruxal reads every Gaudium IVF and Women Health Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Get every filing that moves a stock

One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.

Cruxal publishes market coverage for information only. Nothing here is investment advice.